STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: Novel STAT3 inhibitor BP-5087, derived from SF-1-066, demonstrated 10-fold greater potency in reducing STAT3 phosphorylation and translocation, inhibiting survival of TKI-resistant CML cells and LSCs in preclinical studies [18,142].